References
1. Ferrari S.M., et al. Chemokines in hyperthyroidism. J Clin Transl Endocrinol. 2019; 16: 100196.
2. Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001; 7 (6): 451–60.
3. Lane L.C., et al. New therapeutic horizons for Graves’ hyperthyroidism. Endocr Rev. 2020; 41 (6): 873–84.
4. Wemeau J.-L., et al. Graves’ disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris). 2018; 79 (6): 599–607.
5. Molnár I. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves’ disease during methimazole therapy. Autoimmunity. 2007; 40 (1): 31–7.
6. Crescioli C., et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007; 195 (1): 145–55.
7. Antonelli A., et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf). 2006; 64 (2): 189–95.
8. Antonelli A., et al. Graves’ disease: epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020; 34 (1): 101387.
9. Zarković M. The role of oxidative stress on the pathogenesis of Graves’ disease. J Thyroid Res. 2012; 2012: 302537.
10. Venditti P., Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci. 2006; 63 (4): 414–34.
11. Song Y., et al. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab. 2007; 92 (10): 3764–73.
12. Marcocci C., Leo M., Altea M.A. Oxidative stress in Graves’ disease. Eur Thyroid J. 2012; 1 (2): 80–7.
13. Vejrazkova D., et al. Genetic predictors of the development and recurrence of Graves’ disease. Physiol Res. 2018; 67 (suppl 3): S431–9.
14. Troshina E.A., et al. Clinical guidelines for the diagnosis and treatment of thyrotoxicosis with diffuse goiter (Graves’ disease) and nodular/multinodular goiter. 2021. (in Russian)
15. Akasu F., et al. Studies of CD4+ (helper/inducer) T lymphocytes in autoimmune thyroid disease: demonstration of specific induction in response to thyroid peroxidase (TPO) in vitro and its relationship with thyroid status in vivo. Thyroid. 1991; 1 (3): 215–22.
16. Dogadin S.A., Dudina M.A., Savchenko A.A., Man’kovsky V.A., Gvozdev I.I. Respiratory burst activity in neutrophilic granulocytes in the onset of Graves’ disease. Problemy endokrinologii [Problems of Endocrinology]. 2017; 63 (1): 4–8. (in Russian)
17. Abalovich M., et al. Peripheral parameters of oxidative stress in Graves’ disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf). 2003; 59 (3): 321–7.
18. Bednarek J., Wysocki H., Sowiński J. Oxidative stress peripheral parameters in Graves’ disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin Biochem. 2005; 38 (1): 13–8.
19. Rybus-Kalinowska B., et al. Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism. Pol Arch Med Wewn. 2008; 118 (7–8): 420–5.
20. Aslan M., et al. Evaluation of oxidative status in patients with hyperthyroidism. Endocrine. 2011; 40 (2): 285–9.
21. Blick C., Nguyen M., Jialal I. Thyrotoxicosis. Treasure Island, FL, 2022.